Harmony Biosciences Inc. (HRMY)
28.48
0.54 (1.93%)
At close: Apr 17, 2025, 3:59 PM
1.93% (1D)
| Bid | 27.27 |
| Market Cap | 1.63B |
| Revenue (ttm) | 714.73M |
| Net Income (ttm) | 145.49M |
| EPS (ttm) | 2.51 |
| PE Ratio (ttm) | 11.35 |
| Forward PE | 7.03 |
| Analyst | Buy |
| Ask | 28.79 |
| Volume | 353,404 |
| Avg. Volume (20D) | 710,937 |
| Open | 27.95 |
| Previous Close | 27.94 |
| Day's Range | 27.95 - 28.53 |
| 52-Week Range | 26.47 - 41.61 |
| Beta | 0.80 |
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmo...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 19, 2020
Employees 268
Stock Exchange NASDAQ
Ticker Symbol HRMY
Analyst Forecast
According to 12 analyst ratings, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is $52.5, which is an increase of 84.34% from the latest price.
Stock ForecastsNext Earnings Release
Harmony Biosciences Inc. is scheduled to release its earnings on Apr 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-9.64%
Harmony Biosciences shares are trading lower after...
Unlock content with
Pro Subscription
5 months ago
-18.53%
Harmony Biosciences shares are trading lower after the company announced a public offering of up to 8 million shares of common stock by selling shareholders Marshman Fund Trust II and Valor IV Pharma Holdings.
